Mpox Can Infect and Replicate in the Brain, US Health Researchers Say in Fatal HIV Case

Why It Matters

Neuroinvasion and antiviral resistance in mpox raise the risk of severe disease, especially among HIV‑positive populations, demanding urgent investment in detection and treatment strategies.

Key Takeaways

• Mpox detected replicating in brain of HIV patient
• Virus showed resistance mutations to tecovirimat
• Global health funding cuts may worsen mpox/HIV co‑infection
• Clade IIb strain linked to severe systemic spread
• Autopsy underscores need for better antivirals

Pulse Analysis

The discovery that mpox can invade and replicate within the central nervous system reshapes our understanding of the virus’s pathogenic potential. While mpox has traditionally been associated with cutaneous lesions, the NIH‑led autopsy demonstrates that, in immunocompromised hosts such as individuals with advanced HIV, the virus can cross the blood‑brain barrier and establish a persistent reservoir. This neurotropic behavior not only complicates clinical management but also raises the specter of long‑term neurological sequelae, prompting a reevaluation of diagnostic protocols that have largely focused on skin manifestations.

Compounding the threat is the emergence of tecovirimat‑resistant mutations identified in the patient’s viral genome. Tecovirimat, once heralded as a frontline oral therapy for mpox, has shown limited benefit in recent trials, and resistance further erodes its utility. The case highlights the pressing need for a diversified antiviral pipeline, including agents targeting different stages of the viral life cycle. Researchers and pharmaceutical firms must accelerate clinical testing of novel compounds, while public‑health agencies should prioritize resistance monitoring to inform treatment guidelines.

The broader implications extend beyond a single fatality. As global health financing contracts, especially for HIV programs in Africa, the convergence of untreated HIV and circulating mpox clades creates a fertile environment for prolonged infections and viral evolution. Strengthening surveillance, ensuring uninterrupted HIV care, and investing in vaccine and therapeutic development are essential to prevent a resurgence of severe mpox outbreaks. Policymakers must recognize the intertwined nature of these diseases and allocate resources accordingly to safeguard both public health and economic stability.